We use cookies to improve the website and your navigation experience. To accept cookies continue to browse the site or click here For more information on how we use cookies and how to disable them, please visit our Cookies Policy Map | Contact us | Sweden ---------- Celgene Global Asia Australia Austria Belux Canada China Denmark Europe Finland France Germany Ireland Italy Japan The Netherlands Norway Russia Spain Taiwan Turkey United Kingdom Print Page About us R&D Healthcare staff Patients Cancer organizations Press center Career Investor Relations Celgene Corporation has been awarded the prestigious EURORDIS Company Award for excellence in the field of rare diseases. The award, presented just in advance of Rare Diseases Day, February 28, recognizes Celgene's established track record in the area of orphan diseases, with multiple orphan designations and approved disease-altering therapies addressing patient needs and a robust pipeline of innovative compounds under development. Press release Celgene AB and its employees work hard to be able to offer solutions to unsatisfied medical needs in cancer and debilitating inflammatory diseases. In Europe, Celgene currently has three drugs registered for the treatment of the haematological cancers myeloma and myelodysplastic syndromes. More than 200 clinical trials are underway at major medical centers around the world, with innovative substances from Celgene. The substances in these studies are actively investigated in clinical trials for patients with incurable hematological, as well as solid, cancerous tumors and inflammatory diseases. Using the latest advances in molecular and cell biological research in the development of new therapies that seek the disease mechanisms at the source, Celgene makes potentially life-saving treatments a reality for the millions of patients worldwide battling cancer and other debilitating diseases. Information on Celgene-sponsored clinical trials can be found at:> http://clinicaltrials.ifpma.org/ EFPIA publication of value transfers from the pharmaceutical industry to healthcare professionals or other healthcare As a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), Celgene supports and meets the requirements of the EFPIA Code on open reporting of value transfers from the pharmaceutical industry to healthcare professionals or other healthcare professionals. Our collaboration with healthcare is an important and necessary step in developing innovative medicines, as well as in ensuring the safe and correct use of these medicines for the greatest benefit of patients. For more information visit lif.se Investigate: Who we are Our company history or Contact us This website is intended for people who are in Sweden. Click on the following links to move to Celgene's other websites: Celgene Global: http://www.celgene.com/ Celgene Asia: http://www.celgene.asia/ Celgene Europe: http://www.celgene.eu/ @ 2009-2014, Celgene AB Privacy Policy | Terms of Use | Cookies Policy